2008 NME approvals no better than last year?

In 2007, there was much ado about the slow pace of new molecular entity (NME) approvals. Though over 200 drugs were approved in 2007, only 19 of them represented groundbreaking advances in medicine.

In 2008, according to a post on Pharmalot, the industry is set to repeat last year's lackluster performance. Thus far the FDA has approved 14 NDAs but only one NME--the same rate of approval as last year. Why so slow? Analyst Jim Kumpel of Friedman Billings Ramsey says the FDA is hard at work implementing initiatives that resulted from PDUFA reauthorization. Others, including industry execs, are likely to blame the slowdown on a skittish post-Vioxx FDA that's suffered serious criticism for approving unsafe drugs.

- here's the Pharmalot item
- see the full list of 2007 FDA approvals

Related Articles:
Dry spell or parched desert for NME approvals? Report
'07's drug approval record raises worries. Report
New drug approval lags in 2007. Report
FDA quick to reject drugs as it gets more cautious. Report
Industry exec says FDA approval process too strict. Report

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.